SABCS 2022 Conference Coverage


 

SABCS 2022 Updated Survival Results of the Randomized Phase 3 Study DESTINY-Breast03: T-DXd vs. Trastuzumab Emtansine in Patients With HER2+ mBC

259 views
December 14, 2022
Comments 0
Login to view comments. Click here to Login